GlassScriptPhysician profile
Christian Chaban
NPI 1396163630
$1,384.27
in general payments reported to CMS, 2019-2025
24 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $104 · 2021: $240 · 2022: $220 · 2023: $91.62 · 2024: $365 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $140.68 | 2019-2022 | |
| Cranial Technologies, INC | $135.60 | 2019-2025 | Doc Band |
| Neurelis, INC. | $131.68 | 2023-2024 | Valtoco |
| Tris Pharma INC | $118.31 | 2019-2022 | |
| Ucb, INC. | $95.66 | 2024-2025 | Briviact, Nayzilam |
| Sanofi Pasteur INC. | $81.49 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $73.56 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $67.24 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $60.88 | 2022-2023 | |
| Abbvie INC. | $56.38 | 2020-2022 | |
| Adlon Therapeutics L.P. | $56.33 | 2021 | |
| Corium, LLC | $44.17 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $43.10 | 2024 | Daybue |
| Verrica Pharmaceuticals INC. | $43.00 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $40.41 | 2024 | Vaxneuvance, Gardasil 9, Vaxelis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $39.20 | 2019-2024 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $36.65 | 2020-2022 | |
| Biogen, INC. | $23.28 | 2025 | Spinraza |
| Seqirus USA INC | $22.49 | 2024 | Flucelvax |
| Cipher Pharmaceuticals US LLC | $17.43 | 2025 | Spinosad, Natroba |
| Shire North American Group INC | $15.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.99 | 2022 | |
| Kaleo, INC. | $13.06 | 2019 | |
| Neos Therapeutics, LP | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Chaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.